… Data from the clinical trials suggested efficacy in clinical, endoscopic, and histological …
Crohn’s disease and with Crohn’s fistulas (2–6). The clinical experience with infliximab in Crohn’s …

… this study was to assess our clinical experience with infliximab, a monoclonal antitumor
necrosis factor antibody, following its approval for treatment of refractory Crohn’s disease (CD). …

… disease at the time tertiary referral is needed being less well described. The greatest concern
for patients with Crohn's disease … to determine the clinical spectrum of Crohn's disease in a …

… factors for progressive disease in luminal CD can be found in Table 3. From clinical experience,
… as those at risk for progressive disease: extensive small bowel disease, severe upper GI …

Background & Aims : The aim of this study was to evaluate the short- and long-term safety of
infliximab in patients with Crohn’s disease in clinical practice. Methods : The medical …

… Reports from clinical experience with anti-TNF-α treatment may be valuable for clinicians …
In a Swedish report of long-term clinical experience with CD patients receiving infliximab, 13% …

Background: Inadequate response to infliximab [IFX] therapy in Crohn’s disease [CD] may
necessitate dose intensification. We evaluated safety and efficacy of high-dose IFX [HD IFX] […

… or recrudescence of Crohn's disease anywhere along the … without previous surgery for
Crohn's disease, a covariate analysis … Finally in 236 patients with Crohn's disease limited to one …

Results Fifteen female patients with a median age of 28 years (interquartile range: 28–44
years) suffering from Crohn’s disease of the ileum (27%), colon (33%) and ileocolon (40%) …

… seen in controlled clinical trials (5-7). We examined the initial clinical experience with
infliximab in the treatment of refractory inflammatory and fistulizing Crohn's disease at four referral …